Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Retained Earnings (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Retained Earnings for 14 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 99.58% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, down 99.58% year-over-year, with the annual reading at $2.3 million for FY2025, 99.58% down from the prior year.
  • Retained Earnings hit $2.3 million in Q4 2025 for Corcept Therapeutics, down from $2.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $599.4 million in Q2 2025 to a low of -$2.1 million in Q2 2022.
  • Historically, Retained Earnings has averaged $109.4 million across 5 years, with a median of $650500.0 in 2023.
  • Biggest five-year swings in Retained Earnings: crashed 642.57% in 2022 and later skyrocketed 1034957.78% in 2024.
  • Year by year, Retained Earnings stood at -$227000.0 in 2021, then crashed by 282.82% to -$869000.0 in 2022, then soared by 170.08% to $609000.0 in 2023, then soared by 89183.25% to $543.7 million in 2024, then tumbled by 99.58% to $2.3 million in 2025.
  • Business Quant data shows Retained Earnings for CORT at $2.3 million in Q4 2025, $2.3 million in Q3 2025, and $599.4 million in Q2 2025.